WO2002069946A3 - Verwendung von triazolverbindungen zur prophylaxe und therapieneurodegenerativer erkrankungen, hirntrauma und zerebraler ischämie - Google Patents

Verwendung von triazolverbindungen zur prophylaxe und therapieneurodegenerativer erkrankungen, hirntrauma und zerebraler ischämie Download PDF

Info

Publication number
WO2002069946A3
WO2002069946A3 PCT/EP2002/002203 EP0202203W WO02069946A3 WO 2002069946 A3 WO2002069946 A3 WO 2002069946A3 EP 0202203 W EP0202203 W EP 0202203W WO 02069946 A3 WO02069946 A3 WO 02069946A3
Authority
WO
WIPO (PCT)
Prior art keywords
prophylaxis
therapy
triazole compounds
cerebral ischaemia
illnesses
Prior art date
Application number
PCT/EP2002/002203
Other languages
English (en)
French (fr)
Other versions
WO2002069946A2 (de
Inventor
Dorothea Starck
Gerd Steiner
Laszlo Szabo
Berthold Behl
Francisco Javier Garci-Ladona
Liliane Unger
Original Assignee
Abbott Gmbh & Co Kg
Dorothea Starck
Gerd Steiner
Laszlo Szabo
Berthold Behl
Francisco Javier Garci-Ladona
Liliane Unger
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Gmbh & Co Kg, Dorothea Starck, Gerd Steiner, Laszlo Szabo, Berthold Behl, Francisco Javier Garci-Ladona, Liliane Unger filed Critical Abbott Gmbh & Co Kg
Priority to AU2002242713A priority Critical patent/AU2002242713A1/en
Publication of WO2002069946A2 publication Critical patent/WO2002069946A2/de
Publication of WO2002069946A3 publication Critical patent/WO2002069946A3/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Die Erfindung betrifft die Verwendung von Triazolverbindungen zur Prophylaxe und Therapie neurodengenerativer Erkrankungen, Hirntrauma und zerebraler Ischämie, insbesondere Schlaganfall, und den durch diese Erkranjungen hervorgerufenen Folgeerkrankungen.
PCT/EP2002/002203 2001-03-01 2002-02-28 Verwendung von triazolverbindungen zur prophylaxe und therapieneurodegenerativer erkrankungen, hirntrauma und zerebraler ischämie WO2002069946A2 (de)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002242713A AU2002242713A1 (en) 2001-03-01 2002-02-28 Use of triazole compounds for prophylaxis and in therapy for neurodegenerative illnesses, brain traumas and cerebral ischaemia

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10109867A DE10109867A1 (de) 2001-03-01 2001-03-01 Verwendung von Triazolverbindungen zur Prophylaxe und Therapie neurodegenerativer Erkrankungen, Hirntrauma und zerebraler Ischämie
DE10109867.7 2001-03-01

Publications (2)

Publication Number Publication Date
WO2002069946A2 WO2002069946A2 (de) 2002-09-12
WO2002069946A3 true WO2002069946A3 (de) 2002-12-12

Family

ID=7675937

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2002/002203 WO2002069946A2 (de) 2001-03-01 2002-02-28 Verwendung von triazolverbindungen zur prophylaxe und therapieneurodegenerativer erkrankungen, hirntrauma und zerebraler ischämie

Country Status (3)

Country Link
AU (1) AU2002242713A1 (de)
DE (1) DE10109867A1 (de)
WO (1) WO2002069946A2 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2011008335A (es) 2009-02-06 2011-09-06 Ortho Mcneil Janssen Pharm Novedosos compuestos heterociclicos biciclicos sustituidos como moduladores de la gamma secretasa.
CA2778517A1 (en) 2009-07-15 2011-01-20 Janssen Pharmaceuticals, Inc. Substituted triazole and imidazole derivatives as gamma secretase modulators
KR20120123677A (ko) 2010-01-15 2012-11-09 얀센 파마슈티칼즈, 인코포레이티드 감마 세크레타제 조절제로서의 신규 치환된 비사이클릭 트리아졸 유도체
BR112013023984A2 (pt) 2011-03-24 2016-09-13 Cellzome Ltd derivados triazolil piperazina e triazolil piperidina substituidos como moduladores de gama secretase
TWI567079B (zh) 2011-07-15 2017-01-21 健生醫藥公司 作為伽瑪分泌酶調節劑之新穎的經取代的吲哚衍生物
MX355164B (es) 2012-05-16 2018-04-06 Janssen Pharmaceuticals Inc Derivados de 3,4-dihidro-2h-pirido[1,2-a]pirazin-1,6-diona sustituidos utiles para el tratamiento de la enfermedad de alzheimer (inter alia).
JP6275161B2 (ja) 2012-12-20 2018-02-07 ヤンセン ファーマシューティカ エヌ．ベー． γセクレターゼ調節剤としての新規な三環式３，４−ジヒドロ−２Ｈ−ピリド［１，２−ａ］ピラジン−１，６−ジオン誘導体
JP6283691B2 (ja) 2013-01-17 2018-02-21 ヤンセン ファーマシューティカ エヌ．ベー． γセクレターゼ調節剤としての新規な置換ピリド−ピペラジノン誘導体
US10562897B2 (en) 2014-01-16 2020-02-18 Janssen Pharmaceutica Nv Substituted 3,4-dihydro-2H-pyrido[1,2-a]pyrazine-1,6-diones as gamma secretase modulators
CN107474008B (zh) * 2017-09-29 2020-01-14 河南师范大学 一种α-甲酰基四氢吡啶类化合物的合成方法

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4338453A (en) * 1980-09-17 1982-07-06 The Upjohn Company Aminoalkyl-1,2,4-triazoles
EP0345948A2 (de) * 1988-05-06 1989-12-13 SMITHKLINE BEECHAM PHARMA GmbH Verwendung von 5-HT1A Agonisten zur Herstellung eines Arzneimittels, das gegen ischämische Verletzungen Schützt
WO1996002520A1 (de) * 1994-07-15 1996-02-01 Basf Aktiengesellschaft Triazolverbindungen und deren verwendung als dopamin-d3-liganden
WO1996004287A1 (fr) * 1994-07-29 1996-02-15 Laboratorios Del Dr. Esteve, S.A. Tetrahydropyridine-(ou 4-hydroxypiperidine) alkylazoles ayant une activite pour les recepteurs sigma et/ou 5ht1a
WO1999002503A1 (de) * 1997-07-07 1999-01-21 Basf Aktiengesellschaft Triazolverbindungen und deren verwendung als dopamin-d3-liganden
WO2000067847A2 (de) * 1999-05-07 2000-11-16 Basf Aktiengesellschaft Verwendung von dopamin-d3-rezeptorliganden zur herstellung von arzneimittel für die behandlung von nierenfunktionsstörungen
WO2001072306A1 (de) * 2000-03-27 2001-10-04 Basf Aktiengesellschaft Verwendung von dopamin-d3-rezeptor-liganden zur behandlung von erkrankungen des zentralen nervensystems

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4338453A (en) * 1980-09-17 1982-07-06 The Upjohn Company Aminoalkyl-1,2,4-triazoles
EP0345948A2 (de) * 1988-05-06 1989-12-13 SMITHKLINE BEECHAM PHARMA GmbH Verwendung von 5-HT1A Agonisten zur Herstellung eines Arzneimittels, das gegen ischämische Verletzungen Schützt
WO1996002520A1 (de) * 1994-07-15 1996-02-01 Basf Aktiengesellschaft Triazolverbindungen und deren verwendung als dopamin-d3-liganden
WO1996004287A1 (fr) * 1994-07-29 1996-02-15 Laboratorios Del Dr. Esteve, S.A. Tetrahydropyridine-(ou 4-hydroxypiperidine) alkylazoles ayant une activite pour les recepteurs sigma et/ou 5ht1a
WO1999002503A1 (de) * 1997-07-07 1999-01-21 Basf Aktiengesellschaft Triazolverbindungen und deren verwendung als dopamin-d3-liganden
WO2000067847A2 (de) * 1999-05-07 2000-11-16 Basf Aktiengesellschaft Verwendung von dopamin-d3-rezeptorliganden zur herstellung von arzneimittel für die behandlung von nierenfunktionsstörungen
WO2001072306A1 (de) * 2000-03-27 2001-10-04 Basf Aktiengesellschaft Verwendung von dopamin-d3-rezeptor-liganden zur behandlung von erkrankungen des zentralen nervensystems

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SARVA MARIA CONCETTA ET AL: "Triazole derivatives as 5-HT1A serotonin receptor ligands.", BIOORGANIC & MEDICINAL CHEMISTRY, vol. 10, no. 2, February 2002 (2002-02-01), February, 2002, pages 313 - 323, XP002208153, ISSN: 0968-0896 *

Also Published As

Publication number Publication date
AU2002242713A1 (en) 2002-09-19
DE10109867A1 (de) 2002-09-05
WO2002069946A2 (de) 2002-09-12

Similar Documents

Publication Publication Date Title
ZA200401004B (en) Combination for the treatment of inflammatory disorders
IL157734A0 (en) Pharmaceutical compositions for the treatment of urogenital disorders
PL372425A1 (en) Dihydrobenzodiazepin-2-one-derivatives for the treatment of neurological disorders
IL160187A0 (en) Aerosolized decongestants for the treatment of sinusitis
IL162485A0 (en) Compounds for the treatment of inflammatory disorders
AU2002356525A1 (en) Substituted amines for the treatment of neurological disorders
AU2002334870B8 (en) Combinations for the treatment of immunoinflammatory disorders
AU2003228819A1 (en) Combinations for the treatment of inflammatory skin disorders
WO2003088748A8 (en) Use of heme oxygenase-1 and products of heme degradation
WO2002069946A3 (de) Verwendung von triazolverbindungen zur prophylaxe und therapieneurodegenerativer erkrankungen, hirntrauma und zerebraler ischämie
WO2006089664A3 (de) Heterocyclylamid-substituierte imidazole
AU2002319296A1 (en) Use of 2-alkoxyphenyl-substituted imidazotriazinones for the treatment of diseases associated with CGMP regulated processes
AU2002350832A1 (en) Use of irbesartan for the preparation of medicaments that are used to prevent or treat pulmonary hypertension
AU2003247140A1 (en) Delivering compounds to the brain by modifying properties of the bbb and cerebral circulation
AU2003205898A1 (en) Combination therapy for respiratory disorders
AU2002251054A1 (en) Triazole compounds and the use thereof in the prophylaxis and therapy of neurodegenerative diseases, cerebral trauma and cerebral ischemia
AU2003258983A8 (en) Combinations for the treatment of fungal infections
AU2003239967A1 (en) Compound for the treatment of cns disorders
AU2002251202A1 (en) Intimins for the prevention or treatment of infections: i
AU2002336984A1 (en) Use of C2-substituted Indane-1-ol systems for producing medicaments for the prophylaxis or treatment of obesity
AU2002247127A1 (en) Therapy for cerebral vasospasm
AU2002336985A1 (en) Use of C2-substituted Indane-1-one systems for producing medicaments for the prophylaxis or treatment of obesity
AU2002346661A1 (en) Photodynamic therapy for the treatment of epilepsy
TW482068U (en) Improvement of wrench for strap
AU2002324798A1 (en) Pyrazolo-pyridines for the treatment of herpes infections

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP